Travere Therapeutics
TVTX
150 hedge funds and large institutions have $1.56B invested in Travere Therapeutics in 2021 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 58 increasing their positions, 37 reducing their positions, and 23 closing their positions.
61% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 23
57% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 37
11% more call options, than puts
Call options by funds: $3.07M | Put options by funds: $2.76M
10% more capital invested
Capital invested by funds: $1.42B → $1.56B (+$140M)
9% more funds holding
Funds holding: 138 → 150 (+12)
1.51% more ownership
Funds ownership: 102.46% → 103.98% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$67.4M |
| 2 |
AC
Armistice Capital
New York
|
+$65.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$47M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$29.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$26.1M |
| 2 |
SCM
Scopia Capital Management
New York
|
-$20.2M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$15.2M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$12.9M |
| 5 |
Millennium Management
New York
|
-$8.05M |
TVTX Hedge Fund Activity: Q1 2021 in Review
150 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2021, worth a combined $1.56B — up 9.8% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new TVTX positions and 23 closed out — a net gain of 14 holders — while 58 added to existing stakes and 37 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $67.4M. The largest seller was Citadel Advisors, cutting an estimated $26.1M.
- 150 institutional investors held Travere Therapeutics (TVTX) as of Q1 2021, up from 138 in Q4 2020.
- Funds reported $1.56B of Travere Therapeutics stock for Q1 2021, up 9.8% quarter-over-quarter.
- 37 funds opened new Travere Therapeutics positions in Q1 2021 and 23 closed out, a net change of +14 holders.
- The largest Travere Therapeutics buyer in Q1 2021 was State Street, an estimated $67.4M added.
- The largest Travere Therapeutics seller in Q1 2021 was Citadel Advisors, an estimated $26.1M sold.
Based on aggregated 13F filings for Q1 2021.